Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 3/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.44 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | CTSD | P07339 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31559098 | 0.94 | CASP3 (0.51) | CASP3PTPN1ELANECTSBCTSK | |
| SCHEMBL26923683 | 0.91 | CASP3 (0.54) | CASP3PTPN1 | |
| SCHEMBL23106467 | 0.87 | PTPN1 (0.47) | CASP3PTPN1CTSK | |
| SCHEMBL23106599 | 0.87 | PTPN1 (0.47) | CASP3PTPN1CTSK | |
| SCHEMBL31217893 | 0.87 | PTPN1 (0.48) | CASP3PTPN1CTSK | |
| SCHEMBL31559103 | 0.87 | CASP3 (0.50) | CASP3PTPN1ELANECTSDCA2 | |
| SCHEMBL30715198 | 0.86 | CASP3 (0.49) | CASP3PTPN1 | |
| SCHEMBL31559011 | 0.85 | CASP3 (0.58) | CASP3PTPN1 | |
| SCHEMBL31217797 | 0.84 | CASP3 (0.46) | CASP3PTPN1 | |
| SCHEMBL26923733 | 0.84 | CASP3 (0.57) | CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4536666-A1 | ANTIBODY DRUG CONJUGATES | BeiGene, Ltd. (KY) | 2025-04-16 | — | — | EP | disclosed |
| US-20250099607-A1 | ANTIBODY DRUG CONJUGATES | BEIGENE, LTD. (KY) | 2025-03-27 | — | — | US | disclosed |
| WO-2023237050-A1 | ANTIBODY DRUG CONJUGATES | BEIGENE, LTD. (KY) | 2023-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250099607-A1 | ANTIBODY DRUG CONJUGATES | CD22, FCGR2A, FCGR3B | CASP3 4072/4885PTPN1 2278/4885ELANE 3280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.